ChangeWave Issues Buy Recommendation on Access Pharmaceuticals
November 17 2009 - 9:00AM
PR Newswire (US)
DALLAS, Nov. 17 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS,
INC. (OTC:ACCP) (BULLETIN BOARD: ACCP) today announced that a
recommendation report was issued by ChangeWave, a research network
that identifies emerging trends and companies best-positioned to
capitalize in today's marketplace. The report was written by Mr.
Joshua Levine, Editor of ChangeWave Investing and ChangeWave
MicroCap Investor. According to Mr. Levine, "Finally, with MuGard
now commercialized, Access is already receiving its first
royalties, and cash flow will steadily ramp up in the coming
quarters. Since MuGard has pharmaceutical-type margins, it will
instantly impact Access' financial situation. The increase in
revenue will provide financial security for this company with an
active partnering and outsourcing model and a very small $3
million-a-year burn rate." Mr. Levine also cited, "Looking at its
pipeline, Access is involved in discussions with potential regional
and global partners for a ProLindac license covering North America
and Europe, which together represent at least 80% of the overall
market. The company also intends to initiate additional ProLindac
Phase II combo trials globally." "We are pleased to have Access be
highlighted by ChangeWave, a well-respected research firm that has
a vast audience base looking for emerging growth companies that are
in the proper position to capitalize on emerging trends," stated
Jeffrey Davis, Access' President & CEO. To obtain the full
report or future write-ups on Access, go to
http://www.changewave.com/ and subscribe to the ChangeWave MicroCap
Investor newsletter. About ChangeWave: ChangeWave, a subsidiary of
InvestorPlace Media, LLC, was founded in 2001, with the goal of
creating a world-class expert research network to identify emerging
trends, technologies and companies best-positioned to capitalize in
today's market -- and bring it to subscribers well in advance of
other available sources. ChangeWave Research leads one of the
world's leading independent equities and macro-economic research
organizations serving institutional and self-directed private
investors. About Access: Access Pharmaceuticals, Inc. is an
emerging biopharmaceutical company that develops and commercializes
propriety products for the treatment and supportive care of cancer
patients. Access' products include ProLindac(TM), currently in
Phase 2 clinical testing of patients with ovarian cancer, and
MuGard(TM) for the management of patients with mucositis. The
company also has other advanced drug delivery technologies
including Cobalamin(TM)-mediated targeted delivery and oral drug
delivery, its proprietary nanopolymer delivery technology based on
the natural vitamin B12 uptake mechanism; and Thiarabine, a new
generation nucleoside analog which has demonstrated both
pre-clinical and clinical activity in certain cancers. For
additional information on Access Pharmaceuticals, please visit our
website at http://www.accesspharma.com/. This press release
contains certain statements that are forward-looking within the
meaning of Section 27a of the Securities Act of 1933, as amended,
and that involve risks and uncertainties. These statements include
those relating to: clinical trial plans and timelines and clinical
results for ProLindac and product candidates acquired in the
MacroChem transaction, our ability to execute licensing agreements
in the future, Access' plans to continue and initiate clinical
trials, the value of its products in the market (including MuGard
and the size of the overall market for mucositis products), its
ability to achieve clinical and commercial success and its ability
to successfully develop marketed products. These statements are
subject to numerous risks, including but not limited Access' need
to obtain additional financing in order to continue the clinical
trial and operations and to the risks detailed in Access' Annual
Reports on Form 10-K and other reports filed by Access with the
Securities and Exchange Commission. Contact: Company Contact:
Investor Relations Stephen B. Thompson Donald C. Weinberger/Diana
Bittner (media) Vice President, Wolfe Axelrod Weinberger Assoc. LLC
Chief Financial Officer (212) 370-4500 Access Pharmaceuticals, Inc.
(214) 905-5100 DATASOURCE: Access Pharmaceuticals, Inc. CONTACT:
Stephen B. Thompson, Vice President, Chief Financial Officer,
Access Pharmaceuticals, Inc., +1-214-905-5100; Investor Relations,
Donald C. Weinberger or Diana Bittner, both of Wolfe Axelrod
Weinberger Assoc. LLC, +1-212-370-4500 Web Site:
http://www.accesspharma.com/
Copyright